Johnson & Johnson earnings: Expect a slow first quarter due to drug segment challenges

Last year was a strong fiscal year for the company. This one should be more difficult.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.